Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.